Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 April 2000Website:
http://www.exelixis.comNext earnings report:
06 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 2 min agoDividend
Analysts recommendations
Institutional Ownership
EXEL Latest News
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now?
Top-ranked stocks Amazon.com (AMZN), Maplebear Inc. (CART), Exelixis (EXEL) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two companies is the best option for those looking for undervalued stocks?
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
What type of business is Exelixis?
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
What sector is Exelixis in?
Exelixis is in the Healthcare sector
What industry is Exelixis in?
Exelixis is in the Biotechnology industry
What country is Exelixis from?
Exelixis is headquartered in United States
When did Exelixis go public?
Exelixis initial public offering (IPO) was on 17 April 2000
What is Exelixis website?
https://www.exelixis.com
Is Exelixis in the S&P 500?
No, Exelixis is not included in the S&P 500 index
Is Exelixis in the NASDAQ 100?
No, Exelixis is not included in the NASDAQ 100 index
Is Exelixis in the Dow Jones?
No, Exelixis is not included in the Dow Jones index
When was Exelixis the previous earnings report?
No data
When does Exelixis earnings report?
The next expected earnings date for Exelixis is 06 February 2025